Journal Article

Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System

Lacy, Brian E., Omniewski, Nicholas, Bochenek, Wieslaw, Borgstein, Niels, Chang, Lin, Bartolini, Wilmin, Kassebaum, Amy, Shea, Elizabeth, Tripp, Ken, Mallick, Madhuja, Hanlon, Jennifer, Abel, Jessica L., Fox, Susan M., Moshiree, Baha, Boinpally, Ramesh

2021

Overview

Linaclotide improves abdominal pain and constipation in patients with constipation-predominant irritable bowel syndrome (IBS-C). Patients report additional bothersome abdominal symptoms of bloating and discomfort. The intention of this study was to evaluate linaclotide's efficacy in relieving IBS-C-related abdominal symptoms (bloating, discomfort, and pain) using a novel multi-item Abdominal Score (AS). Patients with IBS-C with abdominal pain ≥3 (0-10 scale) were randomized to linaclotide 290 μg or placebo daily for 12 weeks. The AS, derived from the Diary for IBS Symptoms-Constipation, is the average of abdominal bloating, discomfort, and pain at their worst (0 = none, 10 = worst possible). The primary end point was overall change from baseline (CFB) in AS. Secondary end points included CFB in 12-week AS evaluated using cumulative distribution function and 6-week/12-week AS responder (AS improvement ≥2 points for ≥6-week/12-week). Overall, 614 patients (mean age 46.7 years; 81% female) were randomized. All prespecified end points showed significant benefit of linaclotide vs placebo. The mean overall CFB AS reduction for linaclotide was -1.9 vs -1.2 for placebo (P < 0.0001); the 6-week/12-week AS responder rate was 40.5% for linaclotide vs 23.4% for placebo (odds ratio = 2.2 [95% confidence interval, 1.55-3.12; P < 0.0001]). Diarrhea was the most common treatment-emergent adverse event (linaclotide = 4.6%, placebo = 1.6%). Linaclotide significantly reduced multiple abdominal symptoms important to patients with IBS-C (bloating, discomfort, and pain) compared with placebo, as measured by a novel multi-item AS. The AS, derived from the Diary for IBS Symptoms-Constipation, should be considered for use in future IBS-C clinical studies to measure clinically meaningful improvements beyond traditional end points.

• Publisher: Wolters Kluwer,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subject: Abdomen / Abdominal Pain - drug therapy / Adult / Clinical outcomes / Constipation / Constipation - drug therapy / Critical path / Diarrhea / Double-Blind Method / FDA approval / Female / Gastrointestinal Agents - therapeutic use / Gastrointestinal diseases / Guanylyl Cyclase C Agonists - therapeutic use / Humans / Irritable bowel syndrome / Laxatives / Male / Middle Aged / Pain / Patients / Peptides - therapeutic use / Quality of life / Severity of Illness Index / Treatment Outcome